Concert Pharmaceuticals, Inc. (CNCE) News

Concert Pharmaceuticals, Inc. (CNCE): $8.37

0.01 (+0.12%)

POWR Rating

Component Grades








Add CNCE to Watchlist
Sign Up

Industry: Biotech




#216 of 400

in industry

Filter CNCE News Items

CNCE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CNCE News Highlights

  • CNCE's 30 day story count now stands at 2.
  • Over the past 23 days, the trend for CNCE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • SUN are the most mentioned tickers in articles about CNCE.

Latest CNCE News From Around the Web

Below are the latest news stories about CONCERT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNCE as an investment opportunity.

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

LEXINGTON, Mass., February 15, 2023--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.

Yahoo | February 15, 2023

Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

Yahoo | January 23, 2023

5 big deal reports: Sun Pharma’s $576M pact for Concert Pharma

By Davit Kirakosyan

Yahoo | January 22, 2023

Why Concert Pharmaceuticals Stock Rocketed Higher This Week

If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Market Intelligence. The two companies didn't hesitate to point out that this is roughly 33% higher than the latter's 30-day-trailing weighted average share price as of Wednesday, Jan. 18.

Yahoo | January 20, 2023

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. Indeed, Concert Pharmaceuticals...

Yahoo | January 20, 2023

Pharma giant in India buys Concert Pharmaceuticals in $576M deal

An Indian drugmaker will buy Lexington's Concert Pharmaceuticals (NASDAQ: CNCE) in a cash deal valued at an initial $576 million, the two companies announced Thursday.

Yahoo | January 19, 2023

India-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus Milestones

Sun Pharmaceutical Industries Limited, India's top pharmaceutical company, has agreed to acquire Concert Pharmaceuticals Inc (NASDAQ: CNCE) for an upfront payment of $8.00 per share, or $576 million in equity value. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. Concert is a late-stage biotechno

Yahoo | January 19, 2023

UPDATE 2-India's Sun Pharma acquires U.S.-based Concert for $576 mln

Sun Pharmaceutical Industries Limited , India's largest drugmaker, said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to its experimental drug for treating patchy baldness. The deal is the Indian drugmaker's biggest since its $3.2 billion acquisition of generic drugmaker Ranbaxy Laboratories Ltd in 2014, according to Refinitiv data. Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock's last close.

Yahoo | January 19, 2023

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

MUMBAI & LEXINGTON, Mass., January 19, 2023--Sun Pharma to acquire Concert Pharmaceuticals.

Yahoo | January 19, 2023

Concert (CNCE) Moves 19.3% Higher: Will This Strength Last?

Concert (CNCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | January 9, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7671 seconds.